about
Pazopanib, a new therapy for metastatic soft tissue sarcomaA Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.Combining targeted agents with modern radiotherapy in soft tissue sarcomas.STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.Advances in paediatric cancer treatmentProactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Clinical pharmacology of axitinib.Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Axitinib plasma pharmacokinetics and ethnic differences.Pazopanib for the treatment of renal cell carcinoma.Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.PharmGKB summary: pazopanib pathway, pharmacokinetics.Generation of small molecules to interfere with regulated necrosis.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.Individualized dosing with axitinib: rationale and practical guidance.In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized 13C-Pyruvate MR Spectroscopy and 18F-FDG PET/CT Imaging in a Mouse Model.A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers.A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.Design, synthesis and biological evaluation of pazopanib derivatives as antitumor agents.Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.
P2860
Q28287163-166C083F-D2A6-451B-920B-773547947BFFQ33433070-45D38A46-5979-4C1E-955A-9928A4AFE01AQ34396047-1F3A1B47-230D-4F98-A85B-6D6B08A8B9EDQ35741417-C78D9580-52AF-442A-8B86-95D99AB57F5BQ36212825-EAC6FC04-8F14-4451-8318-1D3474F14AB3Q36508630-303A7AEF-03C7-4358-A7E7-7311B89E7BE0Q37630186-6E3859B5-F1F6-4AA9-B80E-AA306A206979Q38076349-E2D4010E-12BD-47DC-96B8-7D13986787D9Q38107175-CDE64340-0121-4B34-9046-A0645F78BD38Q38241160-5D0C1D6A-2415-40AA-8376-1AFB0067202FQ38264616-D8E0AD1B-3052-4D08-A81D-93E2D45ED42FQ38348548-B5E0B677-517F-4F33-93C8-07E382937B77Q38400468-1F6D0F73-9FF4-4847-B9CE-37E25124AEC9Q38481540-A353381E-3786-430B-918D-01930A6FDA40Q38653213-30909020-91E4-4840-AA4A-BF8CDB3A161CQ38693146-AA972D26-D892-448D-A6A7-F029150B9029Q38799144-66D4C9E7-D513-4AD4-84E2-12DF0BF3A825Q39204706-D81902CD-6062-4833-93CB-1CE8F95D8508Q39415429-E2F1CE7A-6F36-4E7D-AD2C-9F64E4F5F2FEQ39514813-8C3A4557-9912-455B-BE03-D2B8F0900B33Q47271327-8A9C0DC8-BCC5-475C-A488-2315502C4BE5Q47698844-2A4B5CDB-2851-4173-97BD-7441A2AC2E28Q48090720-B95E8FA0-4576-45A5-AF91-535DC4C0547EQ49307012-9157DC0A-6B90-4C55-A469-A44E53500B8DQ54403578-28136BB5-2414-4818-A38C-824E87E0DF27Q54976476-DDE07943-044D-49FE-A65F-11A7E63CF6DE
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Concise drug review: pazopanib and axitinib.
@ast
Concise drug review: pazopanib and axitinib.
@en
type
label
Concise drug review: pazopanib and axitinib.
@ast
Concise drug review: pazopanib and axitinib.
@en
prefLabel
Concise drug review: pazopanib and axitinib.
@ast
Concise drug review: pazopanib and axitinib.
@en
P2093
P2860
P1433
P1476
Concise drug review: pazopanib and axitinib.
@en
P2093
Jan H M Schellens
Jos H Beijnen
Robin M J M van Geel
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0055
P577
2012-06-25T00:00:00Z